News | December 10, 2023
Briefs: GlaxoSmithKline Pharmaceuticals and Dr. Reddy's Laboratories
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Demonstrate significant bleed reduction in hemophilia A and B
New facility is part of Aptar Pharma’s global expansion program
Cresemba is the only azole antifungal therapy approved for pediatric patients as young as one affected by these serious, potentially life-threatening infections
This acquisition marks Max Healthcare's entry into Lucknow
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Express Scripts to add Zepbound to National Preferred Formulary
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises
Subscribe To Our Newsletter & Stay Updated
